(Bloomberg) — Pfizer Inc.’s experimental gene therapy for Duchenne muscular dystrophy helped boys with the deadly disease, but failed to match benefits previously shown by competitor Sarepta Therapeutics Inc.All nine of the boys, ages 6 to 12, in the early-stage trial started to produce a key protein called dystrophin after receiving the one-time treatment. While patients with DMD don’t normally make any of the protein needed for muscles to work properly, three boys on a higher dose of the gene therapy produced about 52% of normal levels a year after treatment, Pfizer said in a statement.One boy on the higher …read more
Source:: Yahoo Finance
